论文部分内容阅读
[目的]研究吉非替尼治疗选择性中晚期非小细胞肺癌(NSCLC)患者前后血清乳酸脱氢酶(LDH)的变化。[方法]调查58例服用吉非替尼4周以上的无原发心肝疾病及损伤的以腺癌、女性、不吸烟为主的晚期或复发NSCLC,将病人分成疾病控制组和未控制组,比较治疗前后的血清LDH水平,采用对数配对t检验。[结果]控制组NSCLC38例(PR33例+SD5例),未控制组20例(PD)。控制组治疗前血清LDH值中位数是252mmol/l,治疗后是171mmol/l;未控制组治疗前是212mmol/l,治疗后是273mmol/l,均符合对数正态分布,根据对数和自身前后对照配对t检验,控制组治疗后有显著性降低(P<0.001);未控制组患者治疗后有显著升高(P<0.001)。[结论]血清LDH可协助判断吉非替尼在无原发心肝疾病或损伤的选择性中晚期NSCLC病人疗效。
[Objective] To study the changes of serum lactate dehydrogenase (LDH) before and after gefitinib treatment in patients with advanced non-small cell lung cancer (NSCLC). [Methods] Fifty-eight patients with advanced or recurrent NSCLC, who were treated with gefitinib for more than 4 weeks without primary heart-liver disease and injury, were divided into two groups: control group and uncontrolled group. Serum LDH levels before and after treatment were compared using logarithmic paired t test. [Results] In control group, 38 cases of NSCLC (PR33 + SD 5 cases) and uncontrolled group of 20 cases (PD). The median serum LDH before treatment in the control group was 252 mmol / l, after treatment was 171 mmol / l; uncontrolled group before treatment was 212 mmol / l, after treatment was 273 mmol / l, are in line with the lognormal distribution, according to the logarithm (P <0.001). The uncontrolled patients had a significant increase (P <0.001) after treatment. [Conclusion] Serum LDH can help determine the efficacy of gefitinib in selective advanced non-small cell lung cancer patients with NSCLC.